A Phase 2 Randomized Study to Investigate the Efficacy and Safety of LY2495655 Versus Placebo in Older Patients Undergoing Elective Total Hip Arthroplasty

Status

Recruiting

Phases

Phase 2

Study type

Interventional

Source

JPRN

Registry ID

JPRN-jRCT2080221809

Enrollment

Unknown

Registered

2012-06-01

Start date

2012-06-01

Completion date

Unknown

Last updated

2026-06-29

For informational purposes only — not medical advice. Sourced from public registries and may not reflect the latest updates. Terms

Conditions

Older Patients Undergoing Elective Total Hip Replacement

Interventions

investigational material(s) Generic name etc : LY2495655 INN of investigational material : Therapeutic category code : 399 Agents affecting metabolism, n.e.c. Dosage and Administration for Investigat

Eligibility

Sex/Gender

All

Inclusion criteria

Inclusion criteria: Males with a female partner of childbearing potential should use contraception during the treatment period of the trial and up to 15 weeks after the last dose of investigational product Females should be postmenopausal for at least 1 year at the time of screening Elective total hip arthroplasty (eTHA) is scheduled Have a body mass index of <40 kg/m2 and a weight <136.4 kg Can climb at least 6 stairs with or without holding the handrail (but without human assistance), according to the patient at screening Can stand up from a chair and walk more than 10 meters without human assistance Take at least 12 seconds to perform the Timed Up and Go (TUG) test at screening

Exclusion criteria

Exclusion criteria:

Outcome results

None listed

Source: JPRN (via WHO ICTRP) · Data processed: Jul 3, 2026